Changes in <i>RPS14</i> expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion
Esther N. Oliva(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Roberto Latagliata(Ospedale di Belcolle), Giuliana Alimena, Fortunato Morabito(Azienda Ospedaliera di Cosenza), Maria Cuzzola(University of Messina), Francesco Nobile(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Francesca Ronco(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Maria Antonietta Aloe Spiriti(Sapienza University of Rome), Maria Grazia D’Errigo(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giorgina Specchia(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari), Pasquale Iacopino(Martin University), Carmelo Laganà(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Carlo Finelli(Azienda USL di Bologna), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Antonella Poloni(Marche Polytechnic University), Riccardo Ghio(University of Genoa), Massimo Breccia(Policlinico Umberto I), Sara Galimberti(University of Pisa)
Cited by 29
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464